The research program of the FrontINove IRN is evolutive and will adapt to novel challenges emerging in the field of Immunology. Novel axis or areas of interest will be discussed among partners of the project to define new infra- or extra-network collaborations to support.

The role of pathological nucleic acid sensing pathways in human pathologies, ranging from viral infections, malignancies to auto-immune disorder, has emerged over recent years. The canonical pathway involved in detection of pathological nucleic acids relies on the STING adaptor protein, the activation of which promotes the production of inflammatory cytokines, including type I interferons (IFNα and IFNβ). Notwithstanding the discovery of drugs targeting STING, it is as of today difficult to predict the outcome of activating or inhibiting STING in specific pathologies.

The FontINov network ambitions to use novel and emerging technologies to investigate nucleic acid immunity from new perspectives. To foster and strengthen inter- and trans-disciplinary interactions between the member teams, FrontINov has established an initial consortium coordinated by Nadine Laguette (Molecular Basis of Inflammation, IGH, Montpellier) and the Cigler team (Synthetic Nanochemistry, IOCB, Czech Republic). Transfer of competencies and knowledge throughout the network, together with exchange of material and tools will serve the common purpose of identifying novel therapeutic targets and biomarkers in human pathologies presenting with chronic immune activation and inflammation.

The FrontINov network will organize several networking events, to favour interactions inside the network but also with any researcher or stakeholder interested in taking an active part in this research community.

The FrontINov network is open to new members and additional teams with a strong interest in emerging technologies will be welcome in order to consolidate the network. Please email the project coordinators to express interest.